Crispr Therapeutics Ag
22/100
Smart-money confidence
Bottom band — money moving out
No standout activity across the feeds we track.
Stocks scoring 0–25 beat the S&P 500 39.9% of the time over the next three months, since 2015. How we measured this →
6
hedge funds
hold it · 1 new, 1 added, 3 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Who's behind the signal
Every informed buyer we can see on CRISPR THERAPEUTICS AG, across all three feeds.
Hedge funds · 6
D.E. Shaw & Co
New position
AQR Capital Management
Increased +28%
ARK Invest (Cathie Wood)
Decreased −16%
Tudor Investment (Paul Tudor Jones)
Decreased −2%
Citadel Advisors
Decreased −10%
Millennium Management (Englander)
Unchanged
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
CRISPR THERAPEUTICS AG isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
1
Increasing
3
Decreasing
1
Unchanged
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+28%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.3×
% of portfolio
3.4%
Position change
−16%
3.4% of ARK Invest's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−2%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−10%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
—
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to CRISPR THERAPEUTICS AG
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell CRISPR THERAPEUTICS AG or any security.